TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis

June Wang, Shenlin Du, Wei Fan, Ping Wang, Weiqing Yang and Mingxia Yu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75516-75527. https://doi.org/10.18632/oncotarget.20466

Metrics: PDF 729 views  |   HTML 1335 views  |   ?  


June Wang1,2, Shenlin Du2, Wei Fan1,3, Ping Wang1, Weiqing Yang2 and Mingxia Yu1

1Department of Clinical Laboratory & Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

2Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China

3Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Correspondence to:

Mingxia Yu, email: dewrosy1613@163.com

Keywords: solid tumors, TACC3, survival, prognosis, meta-analysis

Received: March 13, 2017     Accepted: July 26, 2017     Published: August 24, 2017


Recent studies have showed that the transforming acidic coiled coil 3 (TACC3), was aberrantly up-regulated in various solid tumors and was reported to be correlated with unfavorable prognosis in cancer patients. This study aimed to examine the relationship between TACC3 and relevant clinical outcomes. Pubmed, Web of Science, Embase and Cochrane Library were systematically searched to obtain all eligible articles. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the influence of TACC3 expression on overall survival (OS) and disease-free survival (DFS) in solid tumors patients. A total of 1943 patients from 11 articles were included. The result indicated that a significantly shorter OS was observed in patients with high expression level of TACC3 (HR=1.90, 95% CI=1.63–2.23). In the subgroup analysis, the association was also observed in patients with cancers of digestive system (HR=1.85, 95% CI=1.53–2.24). Statistical significance was also observed in subgroup meta-analysis stratified by the cancer type, analysis type and sample size. Furthermore, poorer DFS was observed in patients with high expression level of TACC3 (HR=2.67, 95% CI=2.10–3.40). Additionally, the pooled odds ratios (ORs) showed that increased TACC3 expression was also related to positive lymph node metastasis (OR=1.68, 95% CI=1.26–2.25), tumor differentiation (OR=1.90, 95% CI=1.25–2.88) and TNM stage (OR=1.66, 95% CI=1.25-2.20). In conclusion, the increased expression level of TACC3 was associated with unfavorable prognosis, suggesting that it was a valuable prognosis biomarker or a promising therapeutic target of solid tumors. Further studies should be conducted to confirm the clinical utility of TACC3 in human solid tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20466